In vivo studies showed a marked anti-proliferative and pro-apoptotic activity towards human breast cancer cell lines with PI3K pathway alterations, sufficient to induce a dose-dependent tumor growth delay or regression in PIK3CA-mutant xenografts [75]. This evidence concerns the gene PIK3CA and breast carcinoma.